http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101360948-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2012-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101360948-B1 |
| titleOfInvention | Novel 2-aminoquinazoline derivatives and anticancer agents comprising the same as active ingredients |
| abstract | The present invention relates to a novel aminoquinazoline derivative, specifically, the parent nucleus structure of Formula 1 wherein the 8-position of 2-aminoquinazolin is substituted with piperidine 4-oxy and the 2-amino group is substituted with 6-indazole A novel aminoquinazoline compound having a parental nucleus structure. Such compounds can effectively inhibit the activity of extracellular signal-regulated kinase 1/2 (ERK 1/2), and thus can be effectively used for the prevention and / or treatment of cancers in which cell proliferation is not controlled. |
| priorityDate | 2012-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 464.